Key Takeaways
- High-end delivery, mid-teens guide: Q4 FY22 came in at the top of the upgraded guidance range, and management set initial FY23 revenue growth guidance in the mid-teens.
- Investment cycle will compress margins: FY23 EBITDA margin is guided to ~30% as the company steps up spending on capabilities, IT, and commercial activities in an inflationary environment.
- Tax headwind hits PAT hard: A 200–300 bps increase in the effective tax rate, driven by the phase-out of SEZ benefits, is expected to dilute PAT growth to single digits in FY23.
- Capacity build-out continues: The Hyderabad research facility expansion was completed, microbial and mammalian manufacturing capacity was commissioned, and the Amgen collaboration was extended through 2026 with a new dedicated lab.
- What to watch next quarter: Whether the mid-teens revenue trajectory materializes early in the year, the pace of margin compression toward the 30% floor, and any further clarity on the Mangalore plant’s regulatory approval timeline.
FY22 Performance & Division-Level Drivers
- Q4 catch-up effect: Development Services had a particularly strong quarter, executing both planned work and projects that had been postponed earlier in the year due to supply chain delays and other Covid-related disruption.
- Research divisions sustained momentum: Discovery Services and Dedicated Centres delivered consistent growth throughout the full year, underpinned by steady demand from existing clients.
- SynVent platform gaining traction: The Integrated Drug Discovery platform expanded business from existing clients and attracted new ones, especially from the emerging biopharma segment, making a positive contribution to Discovery Services.
- Covid manufacturing tail persists: The company manufactured remdesivir under a voluntary licence from Gilead and will continue to do so for as long as the pandemic persists, providing a non-recurring revenue stream with an uncertain end date.
Hunt: "I am pleased with the strong finish we had to the year and that we delivered results at the high end of our upgraded guidance range."
Capacity Expansion & Infrastructure
- Hyderabad research facility: Phase three of the expansion was completed during Q4 FY22, bringing the facility’s capacity to approximately 600 scientists, with further expansion planned in the year ahead.
- Biopharma manufacturing scale-up: The company commissioned a cGMP microbial facility and expanded its mammalian cell manufacturing facility, broadening its biologics service offering.
- Small molecule capability extension: Oligonucleotide and highly potent API capabilities were both extended, adding higher-complexity services to the small molecule portfolio.
- Mangalore regulatory catalyst: Plans are on track for the Mangalore manufacturing plant to achieve a major regulatory approval, which would open the site to a broader scope of projects and client types.
Client & Partnership Momentum
- Client addition pace: The company gained more than 100 new clients in the last year, reflecting a broadening base across the CRO and CDMO service spectrum.
- Amgen collaboration deepened: The long-standing, multi-discipline research collaboration with Amgen Inc. was extended to the end of 2026; under the new contract, Syngene will also build and operate a dedicated laboratory to accelerate the scale-up of small molecule projects.
- Demand environment positive: Management sees growing demand for research, development and manufacturing services globally and believes the company is well positioned to capture new opportunities.
Hunt: "Reflecting on the pandemic period, we created more than 1000 new jobs in the last two years and gained more than 100 new clients in the last year. We also extended and expanded our long-term partnership with Amgen Inc. and continued to invest in new capacity and technology to underpin future growth."
Margin & Profitability Outlook
- FY23 EBITDA margin guided to ~30%: The company expects to step up investments in new scientific capabilities, IT and digitisation, and commercial activities; this, combined with the resumption of travel and other business activities post-pandemic in an inflationary environment, is likely to put pressure on margins.
- PAT growth diluted to single digits: With SEZ tax benefits for key operating units reducing in FY23 and in coming years, the effective tax rate is expected to increase by 200 to 300 bps, creating dilution in PAT margin and resulting in single-digit PAT growth for the full year.
- FY24 operating leverage promise: Management expects the step-up in operating investment to position the company for improved growth and operating leverage from FY24, framing FY23 as an investment year.
Guidance & Commitments
| Commitment | Specifics | Timeline |
|---|---|---|
| Revenue growth | Mid-teens growth in revenue from operations | FY23 |
| EBITDA margin | Around 30% | FY23 |
| PAT growth | Single-digit growth, driven by 200–300 bps effective tax rate increase | FY23 |
| Improved growth and operating leverage | Return of operating leverage after the FY23 investment step-up | FY24 |
| Amgen dedicated lab | Build and operate a dedicated laboratory to accelerate small molecule scale-up | By end-2026 |
| Mangalore regulatory approval | Achieve a major regulatory approval to broaden project scope | No date (on track) |
| Hyderabad further expansion | Additional expansion beyond the completed Phase three | Year ahead (FY23) |
| Remdesivir manufacturing | Continue manufacturing under voluntary Gilead licence | As long as pandemic persists |
Key Metrics
| Metric | Q4 FY22 |
|---|---|
| Revenue from operations | ₹758 Cr, +15% YoY and +18% QoQ |
| Total revenue | ₹773 Cr, +14% YoY and +18% QoQ |
| EBITDA | ₹265 Cr, +13% YoY and +23% QoQ |
| EBITDA margin | 34%, vs 35% in Q4 FY21 |
| PAT (before exceptional items) | ₹148 Cr, +7% YoY and +42% QoQ |
| PAT margin (before exceptional items) | 19%, vs 20% in Q4 FY21 |
| EPS (basic) | ₹3.71, vs ₹4.04 in Q4 FY21 and ₹2.57 in Q3 FY22 |
| FY23 revenue growth guidance | Mid-teens, from operations |
| FY23 EBITDA margin guidance | Around 30% |
| FY23 effective tax rate increase guidance | 200–300 bps increase expected |
| FY23 PAT growth guidance | Single digit for the full year |
| Dividend per share (regular + special) | ₹1.00 (50 paisa regular + 50 paisa special), recommended |
| New clients added (last year) | More than 100 |
| IDD project growth (FY22 vs FY21) | ~40% increase in number of projects |
| Scientists at Hyderabad facility | ~600 after phase three completion |